Navigation Links
U of MN study shows link between gene variations and cancer survival
Date:10/22/2008

Scientific research shows that certain genes can influence a person's likelihood to contract particular diseases, cancer for example. New research at the Masonic Cancer Center, University of Minnesota demonstrates that genetic markers may also show a person's likelihood to survive the disease.

A research study led by Brian Van Ness, Ph.D., has successfully identified combinations of genes associated with early clinical relapse of multiple myeloma, a cancer of the white blood cells that produce antibodies. These results raise the possibility that a patient's genetic background exerts an important influence on the patient's prognosis and response to treatment.

"Ultimately, the goal of this research is to predict drug efficacy and toxicity based on a patient's genetic profile, and develop individualized assessments and predictions for the right drug, at the right dose, for the right patient," Van Ness said. This approach offers the dual benefits of avoiding unnecessary treatment for patients less likely to respond to a particular drug, and targeting treatments to those who will benefit most.

The findings are reported in the current issue of the research journal BMC Medicine. Van Ness heads the University's Department of Genetics, Cell Biology, and Development, and conducts research through the Masonic Cancer Center.

In this study, Van Ness and his colleagues used genetic information that the International Myeloma Foundation has gathered from myeloma patients worldwide through its program, Bank On A Cure. This first-of-its-kind program involves several of the major treatment and research centers for myeloma worldwide and thousands of myeloma patients who donate DNA samples to the bank. The University of Minnesota houses one of the program's two DNA banks (the other is in London), and Van Ness is co-director of the program.

"Although myeloma is considered a fatal disease, individual patients have widely varied rates of disease progression and response to treatment because of attributes encoded in their DNA," Van Ness said.

According to Van Ness, the research study findings demonstrate that cancer outcomes differ because patients vary in the ways they absorb, distribute, metabolize, and transport drugs across cell membranes. Individual variations in genes that regulate these biologic processes may not only affect the effectiveness of the drug, but also can result in adverse side effects.

The findings from this study pave the way for similar investigations into other cancers, neurological and cardiovascular conditions, organ transplants, and other diseases.


'/>"/>

Contact: Sara Martin
buss@umn.edu
612-626-7037
University of Minnesota
Source:Eurekalert

Related biology news :

1. NOAA and NSF commission national study of ocean acidification
2. Study of polar dinosaur migration questions whether dinosaurs were truly the first great migrators
3. New CU-Boulder study shows diversity decreases chances of parasitic disease
4. UCSF Fresno leading-edge study lends hope to emphysema patients
5. Study sheds new light on dolphin coordination during predation
6. Current mass extinction spurs major study of which plants to save
7. Study: Wildlife need more complex travel plans
8. UGA study reveals ecosystem-level consequences of frog extinctions
9. Study links nicotine with breast cancer growth and spread
10. Study finds high mortality of endangered loggerhead sea turtles in Baja California
11. Landmark study unlocks stem cell, DNA secrets to speed therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... Jan. 5, 2017  Delta ID Inc., a leader ... technology for automotive at CESĀ® 2017. Delta ID has ... to demonstrate the use of iris scanning as a ... the driver in a car, and as a way ... experience. Delta ID and Gentex will demonstrate ...
(Date:12/22/2016)... 22, 2016 SuperCom (NASDAQ:   ... for the e-Government, Public Safety, HealthCare, and Finance sectors announced today ... been selected to implement and deploy a community-based supportive services program ... California , further expanding its presence in the state. ... This new program, which ...
(Date:12/16/2016)... Research and Markets has announced the addition ... to 2021" report to their offering. ... The biometric vehicle access system market, ... of 14.06% from 2016 to 2021. The market is estimated to ... 854.8 Million by 2021. The growth of the biometric vehicle access ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... /PRNewswire -- WuXi AppTec, a leading global pharmaceutical, ... platform, today announced that it has acquired HD ... discovery contract research organization (CRO). After completion of ... of WuXi, and will continue to focus on ... The acquisition will further strengthen WuXi,s R&D capability ...
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... Minneapolis, Minnesota (PRWEB) , ... January 19, 2017 ... ... contract research organization with services spanning the full spectrum of drug and device ... clinical research services to pharma/device companies and clinicians, today announced Verified Clinical ...
(Date:1/18/2017)... ... 2017 , ... Opal Kelly, a leading producer of powerful ... the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface and ... suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers real-world ...
Breaking Biology Technology: